Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 4/20 | 0.47 |
| ▸ | CCKBR | P32239 | 8/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | CBLB | Q13191 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CCKAR | P32238 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6517828 | 0.86 | KCNH2 (0.46) | OXTRCCKBRKCNH2CCKAR | |
| SCHEMBL6521354 | 0.83 | CCKBR (0.46) | OXTRCCKBRKCNH2CCKAR | |
| SCHEMBL6516243 | 0.82 | CCKBR (0.49) | OXTRCCKBRKCNH2TSHRCCKAR | |
| SCHEMBL6517624 | 0.78 | KCNH2 (0.45) | OXTRCCKBRKCNH2CCKAR | |
| SCHEMBL16498272 | 0.77 | KCNH2 (0.43) | OXTRCCKBRKCNH2CCKAR | |
| SCHEMBL12781055 | 0.75 | CCKBR (0.43) | OXTRCCKBRKCNH2CCKAR | |
| SCHEMBL16498120 | 0.74 | CCKBR (0.42) | CCKBRKCNH2CCKAR | |
| SCHEMBL6517614 | 0.72 | TSHR (0.48) | KDM4ETSHR | |
| SCHEMBL8610939 | 0.72 | SENP1 (0.70) | CCKBR | |
| SCHEMBL4697879 | 0.70 | KCNH2 (0.62) | OXTRCCKBRKCNH2CCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011027156-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2011-03-10 | — | — | WO | disclosed |
| US-20110059043-A1 | CHEMICAL COMPOUNDS | ARROW THERAPEUTICS LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059043-A1 | CHEMICAL COMPOUNDS | CYP2E1, CNR1, CYP3A5 | OXTR 489/4885CCKBR 180/4885KCNH2 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.